News

2019-08-28 | Options X for the control of Influenza

Will be at the ISIRV conference Options X for the control of Influenza

Singapore 28 August-1 September

https://2019.isirv.org

 

2019-06-28 | Annual General Meeting in Vironova Medical AB

 

The shareholders of Vironova Medical AB (publ), 559008-5303, are hereby invited to the Annual General Meeting at 11:00 on the 28th of June 2019 at Vironova Medical’s premises, Gävlegatan 22, 113 30 Stockholm.

 

2019-06-17 | XVIII International Conference on Heterocycles in Bioorganic chemisty

Meet us in Ghent on the 17th-20th of June for the XVIII International Conference on Heterocycles in Bioorganic chemisty. Vironova Medical is the main sponsor of the event. Our Senior Scientist and Chemist Ngarita Kingi will give an oral presentation with the title:

Thionations Using a P4S10-Pyridine Complex.

2018-06-29 | Annual General Meeting in Vironova Medical AB

The shareholders of Vironova Medical AB (publ), 559008-5303, are hereby invited to the Annual General Meeting at 15:00 on 29th June 2018 at Vironova Medical’s premises, Gävlegatan 22, 113 30 Stockholm.

2017-08-25| Vironova Medical AB was nominated to The Rising Star Award at SALSS

Vironova Medical was invited to participate in the renowned Swedish American Life Science Summit SALSS, an annual meeting that brings together scientists, entrepreneurs and investors with the aim is to build strategic and collaborative relationships between academia, industry and fundings.

2017-06-13 | Annual General Meeting in Vironova Medical AB

The shareholders of Vironova Medical AB (publ), 559008-5303, are hereby invited to the Annual General Meeting at 15:00 on 29th June 2017 at Vironova Medical’s premises, Gävlegatan 22, 113 30 Stockholm. Version in Swedish here.

2015-05-06 | Vironova AB (publ) granted new US-patent for an anti-herpes compound.

Vironova Medical AB announces the approval of a new US-patent application. The patent cover topical administration against herpes with B-220 compound in U.S. (US2013310392). The approval enables Vironova to further develop a pharmaceutical formulation for topical administration against herpes simplex virus comprising of the B-220 compound.

2015-04-01 |Vironova AB (publ) granted US patent for a Thionation reagent.

Vironova AB, a leading Nano-Characterization technology and software company announced the approval of a new patent application. The US Patent Office (USPTO) has granted Vironova a patent for a Thionation reagent (no 13/936423). Based on this innovation, Vironova continues to develop the technology for the US market where a number of chemical and pharmaceutical companies are stationed.